Asthma Clinical Trial
Official title:
Efficacy of Vitamin D on the Clinical Management of Pediatric Patients With Asthma in the Hospital General Naval de Alta Especialidad
Asthma is a disease that represents a public health problem worldwide, there are several
barriers, especially in pediatric patients with this disease, them, prevent the adequate
control of their condition, in addition every day there are new processing aids for this
entity; within these novel research we founded the relationship between decreased vitamin D
serum levels and his role in the regulating of the immune response, also this relationship
in the pathophysiology of this disease and responses in the event of infectious diseases of
the respiratory tract which can exacerbate symptoms in pediatric patients. We have been some
of clinical trials with the aim of improving serum levels of vitamin D in asthmatic
patients, however, these studies have different sources of bias and thus far there is no
solid evidence that favors or denies the relationship between asthma and vitamin D, this
paper aims to help generate this evidence to improve clinical management of these patients
and their lung function and increase the free time crisis.
In this trial two study groups which are divided for each of the interventions described
below:
Group low supplementation dose: 1 tablet of 400 IU was administered every 24 hours via oral,
regardless of time or if it is before or after food, preferably in the morning to improve
adherence to treatment, will be completed one year of treatment without suspension.
Group high supplementation dose: 1 tablet of 1600 IU should be administered every 24 hours
via oral, regardless of time or if it is before or after food, preferably in the morning to
improve adherence to treatment, will be completed one year of treatment without suspension
thereof.
There are several potential mechanisms that have been described both in vitro models and in
vivo models in which has been linked to asthma control with elevated levels of vitamin D in
serum. These mechanisms include structural effects in the lungs, immunomodulation,
modulation of smooth muscle response to level and effect on bronchial response to inhaled
medicines to treat asthma.
- Structural mechanisms Studies were conducted in rats of 50 days old, lung compliance
was measured and decreased it in rats whose mothers had a diet of deprivation of
vitamin D compared to those rats whose mothers received vitamin supplementation was
observed. In human groups, pulmonary function tests at age 6 were carried out, and
there was a significant difference between children with mothers with vitamin D
deficiency during pregnancy and children whose mothers had normal levels during
pregnancy. These findings suggest that there is a strong relationship between lung
embryonic development serum level of vitamin D and therefore this plays a key role in
the structural development of the airways
- Anti-inflammatory Mechanisms Within these mechanisms, they are significantly inhibiting
pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor alpha
(TNF-A) by way of inhibition of MAP 38 produced by monocytes. Another such mechanism is
the inhibition of transcription factor (necrosis factor kappa-beta). We observed a
decrease in the phosphorylation and production of reactive oxygen species with the
addition of 1-25 dihydroxyvitamin D levels which leads to less inflammatory damage in
the respiratory epithelium.
- Immunomodulation Effects occur in both innate immunity and adaptive, innate immunity in
the effect of 1,25 hydroxyvitamin D has an effect on the reduction of inflammatory
cytokines and in the decreased expression of Toll-like receptors monocytes. Also active
antimicrobial peptides such as defensin 2 and 4 and the human defensin cathecidina 18,
studies where low levels of vitamin D are associated and low levels of this peptide
- Effects on helper T lymphocytes Molecular effects, vitamin D levels are associated with
decreased circulating IgE as well as decreasing the TH1 response and therefore TH2,
however the role of vitamin D on these cells is unclear, and some studies have shown
the prevalence of TH2 response in patients with adequate levels of Vitamin D, however
the decrease in the inflammatory response and the production of cytokines such as IL 12
has shown that vitamin D it modulates the response that causes pathogenesis Asthma
- Decrease in early infections or severity The previously mentioned effects on adaptive
and innate immunity may decrease the risk of early respiratory tract infections, which
have been associated in the first years of life with a high incidence of wheezing. In
Hawaiian children under age 5 suffering from rickets incidence of respiratory tract
diseases and wheezing it was higher than that of the population without vitamin D
deficiency
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|